September 7, 2016 9:03am

ONVO closed at $3.94 and is UP +$0.50 or 12.69% in the pre-market - BUY

 

 

ONVO has begun commercial contracting for its second tissue service, the ExViveTM Human Kidney. 

  • This kidney proximal tubule model is a natural expansion of ONVO’s preclinical product and service portfolio, allowing customers to study the effects of drug exposure on a key portion of the human kidney relevant to drug discovery and development. 
  • ONVO has already signed multiple commercial orders and is collaborating on toxicology panels and transporter studies, including with two global, top 25 pharmaceutical companies, as part of an early access program.     

 

 

The Bottom Line: ExVive Human Kidney has demonstrated important functional aspects that offer significant value in preclinical testing, including:

  • Demonstrated proximal tubule function for more than four weeks, as measured by gamma-glutamyl transferase (GGT) production;
  • Tissue-like complexity that supports the detection of injury, compensation, and recovery
  • Physiological expression of key transporters as measured by gene and protein expression, which allows for the assessment of kidney toxicity and drug interactions by modeling normal tissue function;
  • Modulatable activity of key renal transporters P-gp, SGLT2, and OCT2, demonstrating a high correlation too difficult to replicate human biology;
  • Demonstrated toxicity of model kidney toxicant cisplatin, and inhibition of toxicity when blocking OCT2 function, demonstrating specific inhibition of cisplatin transport through a known transporter; and
  • Barrier function (permeability) comparable to in-vivo values, as measured by trans-epithelial electrical resistance (TEER).

 

ONVO believes that, as it penetrates the toxicology market, the ExVive Human Kidney tissue service has the potential to grow into the tens of millions in annual revenue and has $100M+ revenue potential in the future as it pursues diligent sales and marketing efforts (inside of a total addressable market of over $2B). 

ONVO closed at $3.94 and is UP +$0.50 or 12.69% in the pre-market